JP Patent

JP7337080B2 — パリペリドンパルミチン酸エステル徐放性懸濁注射液の投薬レジメン

Assigned to 嘉奥制薬（石家庄）有限公司 · Expires 2023-09-01 · 3y expired

What this patent protects

Patent listed against Invega Sustenna.

Drugs covered by this patent

Patent Metadata

Patent number
JP7337080B2
Jurisdiction
JP
Classification
—
Expires
2023-09-01
Drug substance claim
No
Drug product claim
No
Assignee
嘉奥制薬（石家庄）有限公司
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.